脑胶质瘤患者术前血清miR-22-3p、miR-4297水平与临床特征及术后复发的关系

doi:10.19854/j.cnki.1008-2425.2026.01.0004

摘要/Abstract

摘要： 目的探究脑胶质瘤患者术前血清微小核糖核酸-22-3p(miR-22-3p)、微小核糖核酸-4297(miR-4297)水平与临床特征、病理特征及术后复发的关系。方法选取2021年1月到2024年1月共194例脑胶质瘤患者为研究对象,根据术后一年原病灶位置是否复发分为复发组92例和非复发组102例。实时定量荧光PCR(qPCR)法检测脑胶质瘤患者血清miR-22-3p、miR-4297表达水平;多因素Logistic分析脑胶质瘤患者术后复发影响因素;绘制受试者工作特征(ROC)曲线分析血清miR-22-3p、miR-4297水平对脑胶质瘤患者术后复发有预测价值。结果与非复发组脑胶质瘤患者相比,复发组患者血清miR-22-3p和miR-4297水平显著下降(P＜0.05);多因素Logistic回归分析显示临床特征如切除范围和术后放化疗,病理特征如肿瘤直径、病理级别、分化程度、侵袭浸润和血清miR-22-3p、miR-4297水平均为脑胶质瘤术后复发的独立影响因素(P＜0.05);ROC曲线分析表明血清miR-22-3p和miR-4297联合预测脑胶质瘤术后复发的曲线下面积(AUC)值为0.893,显著高于单独预测(miR-22-3p:Z=3.051,P=0.002;miR-4297:Z=2.157,P=0.031) 结论脑胶质瘤术后复发患者血清miR-22-3p、miR-4297水平降低,与临床病理特征相关,两者联合对术后复发预测效能较高。

关键词: 脑胶质瘤, 临床特征, 复发, 微小核糖核酸-22-3p, 微小核糖核酸-4297

Abstract: Objective To investigate the relationship between preoperative serum levels of microRNA-22-3p (miR-22-3p) and microRNA-4297 (miR-4297) and clinical features,pathological characteristics,and postoperative recurrence in patients with glioma. Methods From January 2021 to January 2024,194 patients with glioma were included as the study subjects.According to whether the original lesion location recurred one year after surgery,they were assigned into a recurrence group of 92 cases and a non recurrence group of 102 cases.Real-time quantitative fluorescence PCR (qPCR) was used to detect serum miR-22-3p and miR-4297 in patients with glioma.Multivariate logistic regression was used to explore the influencing factors of postoperative recurrence in patients with glioma.Receiver operating characteristic (ROC) curves were plotted to explore the predictive value of serum miR-22-3p and miR-4297 for postoperative recurrence in glioma patients. Results Compared with the non-recurrence group,patients in the recurrence group had significantly lower serum levels of miR-22-3p and miR-4297 (P＜0.05).Multivariate logistic regression analysis showed that clinical features such as extent of resection and postoperative radiochemotherapy,pathological features such as tumor diameter,pathological grade,differentiation degree,invasion and infiltration,and serum levels of miR-22-3p and miR-4297 were independent factors affecting postoperative recurrence in glioma patients (P＜0.05).The ROC curve analysis indicated that the combined prediction of postoperative recurrence using serum miR-22-3p and miR-4297 had an area under the curve (AUC) of 0.893,which was significantly higher than individual predictions (miR-22-3p:Z=3.051,P=0.002; miR-4297:Z=2.157,P=0.031). Conclusion Serum miR-22-3p and miR-4297 in glioma patients with postoperative recurrence are reduced and correlated with clinical pathological features.The union of the two has a higher predictive effect on postoperative recurrence.

Key words: Glioma, Clinical features, Recurrence, Microribonucleic acid-22-3p, Microribonucleic acid-4297

中图分类号:

R739.41

冯占江, 张钧, 贾海波, 段晓伟, 韩晓正, 张磊, 李一凡. 脑胶质瘤患者术前血清miR-22-3p、miR-4297水平与临床特征及术后复发的关系[J]. 立体定向和功能性神经外科杂志, 2026, 39(1): 22-28.

Feng Zhanjiang, Zhang Jun, Jia Haibo, Duan Xiaowei, Han Xiaozheng, Zhang Lei, Li Yifan. The relationship between preoperative serum miR-22-3p and miR-4297 with clinical features and postoperative recurrence in patients with glioma[J]. Chinese Journal of Stereotactic and Functional Neurosurgery, 2026, 39(1): 22-28.

参考文献

[1] Roda D,Veiga P,Melo JB,et al.Principles in the management of glioblastoma[J].Genes (Basel),2024,15(4):501~528.
[2] Qiao W,Wang Y,Luo C,et al.Development of preoperative and postoperative models to predict recurrence in postoperative glioma patients:a longitudinal cohort study[J].BMC Cancer,2024,24(1):274~286.
[3] Wang XJ,Wang XB,Jiang T,et al.MiR-22-3p suppresses NSCLC cell migration and EMT via targeting RAC1 expression[J].Funct Integr Genom,2023,23(3):281~291.
[4] Zheng Y,Wang Y,Mai RK,et al.Circ_0007534 silencing inhibits the proliferation,migration and invasion and induces the apoptosis of glioma cells partly through down-regulating PROX1 Via elevating miR-22-3p level[J].Cell Mol Neurobiol,2022,42(8):2819~2832.
[5] Fan JL,Zhang L,Bo XH.MiR-126 on mice with coronary artery disease by targeting S1PR2[J].Eur Rev Med Pharmacol Sci,2020,24(2):893~904.
[6] Xu WS,Huang LM,Xie BS,et al.Serum microRNA-4297 is a sex-specific predictive biomarker of glioma grade and prognosis[J].Front Neurol,2022,13(1):888221~888234.
[7] 国家卫生健康委员会医政医管局.脑胶质瘤诊疗规范(2018年版)[J].中华神经外科杂志,2019,35(3):217~239.
[8] Erices JI,Bizama C,Niechi I,et al.Glioblastoma Microenvironment and Invasiveness:New Insights and Therapeutic Targets[J].Int J Mol Sci,2023,24(8):7047~7073.
[9] Li FF,Wang DY,Wang NN,et al.A nomogram with Ki-67 in the prediction of postoperative recurrence and death for glioma[J].Sci Rep,2024,14(1):20334~20344.
[10] Kwon AY,Jeong JY,Park H,et al.miR-22-3p and miR-30e-5p are associated with prognosis in cervical squamous cell carcinoma[J].Int J Mol Sci,2022,23(10):5623~5637.
[11] 曹晶晶,李居怡,曾娟,等.lncRNA NEAT1调控miR-22-3p促进NHE5的表达对神经胶质瘤细胞迁移和侵袭的影响[J].华中科技大学学报(医学版),2022,51(4):474~478.
[12] 孙鹏,牛江涛,梁洪磊,等.微小RNA-22-3p靶向α-烯醇化酶对神经胶质瘤细胞迁移和黏附的影响[J].中华实验外科杂志,2020,37(4):676~679.
[13] Cui SS,Chen YY,Guo YF,et al.Hsa-miR-22-3p inhibits liver cancer cell EMT and cell migration/ invasion by indirectly regulating SPRY2[J].PLoS One,2023,18(2):281536~281546.
[14] Zhou WX,Wang J,Zhang J,et al.LncRNA NCK1-AS1 aggravates hepatocellular carcinoma by the miR-22-3p/YARS axis to activate PI3K/AKT signaling[J].J Gastrointest Liver Dis,2022,31(1):48~59.
[15] Zhang NR,Zang L.MiR-22-3p inhibits 5-fluorouracil resistance in cholangiocarcinoma cells through PTEN/PI3K/AKT axis[J].Assay Drug Dev Technol,2024,22(5):217~228.
[16] Chakraborty S,Nath D.A study on microRNAs targeting the genes overexpressed in lung cancer and their codon usage patterns[J].Mol Biotechnol,2022,64(10):1095~1119.
[17] You GT,Zheng ZY,Huang YL,et al.scRNA-seq and proteomics reveal the distinction of M2-like macrophages between primary and recurrent malignant glioma and its critical role in the recurrence[J].CNS Neurosci Ther,2023,29(11):3391~3405.
[18] Wu HB,Guo CC,Wang CY,et al.Single-cell RNA sequencing reveals tumor heterogeneity,microenvironment,and drug-resistance mechanisms of recurrent glioblastoma[J].Cancer Sci,2023,114(6):2609~2621.
[19] Li C,Li ZX,Zhang MY,et al.An overview of Twist1 in glioma progression and recurrence[M]//Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-Morbidity Factors Part B.Amsterdam:Elsevier,2023,172(1):285~301.
[20] Qiao WY,Wang Y,Luo C,et al.Development of preoperative and postoperative models to predict recurrence in postoperative glioma patients:a longitudinal cohort study[J].BMC Cancer,2024,24(1):274~286.